BigAl, You are right. There are 4 other secondary endpoints, that have results yet to be disclosed, but those compare the treatment groups to the placebos within the trial. Each treatment patient, being their own control, would have to rely on a large external database to set the number of months survival that would be standard for each biomarker profile, if I'm thinking that through correctly.
Market Data 
Markets 
AI
